Daiichi Life Insurance Co. Ltd. Acquires 1,312 Shares of Amgen Inc. $AMGN

Daiichi Life Insurance Co. Ltd. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 34,660 shares of the medical research company’s stock after buying an additional 1,312 shares during the quarter. Daiichi Life Insurance Co. Ltd.’s holdings in Amgen were worth $12,551,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Amgen by 1.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 58,532 shares of the medical research company’s stock worth $21,196,000 after buying an additional 596 shares during the last quarter. CFO4Life Group LLC lifted its holdings in shares of Amgen by 2.6% in the 2nd quarter. CFO4Life Group LLC now owns 1,340 shares of the medical research company’s stock valued at $485,000 after acquiring an additional 34 shares during the last quarter. Madison Wealth Partners Inc lifted its holdings in shares of Amgen by 42.1% in the 2nd quarter. Madison Wealth Partners Inc now owns 996 shares of the medical research company’s stock valued at $361,000 after acquiring an additional 295 shares during the last quarter. X Square Capital LLC grew its position in Amgen by 3.8% in the second quarter. X Square Capital LLC now owns 10,908 shares of the medical research company’s stock worth $3,950,000 after acquiring an additional 397 shares in the last quarter. Finally, Emerald Investment Advisers LLC grew its position in Amgen by 32.4% in the second quarter. Emerald Investment Advisers LLC now owns 15,256 shares of the medical research company’s stock worth $5,525,000 after acquiring an additional 3,735 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of AMGN stock opened at $439.33 on Friday. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $443.20. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The firm has a market capitalization of $237.52 billion, a P/E ratio of 27.30, a P/E/G ratio of 3.17 and a beta of 0.41. The stock has a 50 day moving average price of $379.03 and a 200 day moving average price of $361.95.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the company earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 22.92 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 6,222 shares of company stock valued at $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on AMGN shares. Guggenheim upped their price objective on Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a research report on Monday, August 10th. Barclays lifted their price objective on shares of Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Cantor Fitzgerald increased their target price on shares of Amgen from $350.00 to $400.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. Morgan Stanley reissued an “overweight” rating and issued a $362.00 target price on shares of Amgen in a research note on Wednesday. Finally, Wells Fargo & Company raised their target price on shares of Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $380.43.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Solid operating performance and dividend support the valuation. Amgen’s second-quarter results exceeded expectations, with revenue rising year over year and earnings per share topping consensus. Continued growth and the company’s dividend are helping support investor confidence. Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
• Positive Sentiment: Analysts raised their outlook. Argus increased its price target to $460 from $375 while maintaining a Buy rating, citing the latest quarterly performance and progress across Amgen’s drug portfolio. Separate reports also highlighted favorable forecasts from Mizuho and Cantor Fitzgerald, reinforcing the bullish analyst sentiment. Amgen gets a fresh target
• Positive Sentiment: Tarlatamab development advanced. Amgen’s Phase 3 DeLLphi-315 study is evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer. A successful shot formulation could improve convenience and broaden the commercial potential of the drug. Amgen advances tarlatamab shot versus infusion in Phase 3 lung cancer study
• Positive Sentiment: Trading momentum and options activity were unusually strong. Amgen was identified as a momentum stock after a substantial recent share-price rally, while call-option volume surged well above typical levels, suggesting increased bullish positioning.
• Neutral Sentiment: Valuation is becoming a consideration. With the stock near its recent high and analysts raising targets, some commentary questioned whether much of the favorable news is already reflected in the share price, which could limit near-term upside.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.